Clinical trials: Clopidogrel
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
- Conditions
- Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease
- Trial name
- NCT04007055
- Testing
- Point of care screening for HPR, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Marissa Jarosinski
Clopidogrel, Poor Metabolism of, Carotid Stenosis
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients…
- Trial name
- NCT05566301
- Testing
- Clopidogrel, Ticagrelor
- Where
- Italy
- Volunteers
- 1,140 people
- Sponsor
- IRCCS Policlinico S. Donato
Patients on Clopidogrel, Platelets Transfusion
Frequency of Platelets Transfusion & Post-Operative Bleeding Risk in Patients on Clopidogrel Undergoing CABG
The goal of this retrospective cohort study Is to Primarily be platelet transfusion frequency and postoperative bleeding risk, analysis using descriptive and inferential statistics in all eligible patients admitted to the cardiac…
- Trial name
- NCT07600060
- Where
- Pakistan
- Volunteers
- 227 people
- Sponsor
- Aga Khan University
Acute Ischemic Stroke, Clopidogrel Resistance
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE
The objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction.
- Trial name
- PATH STROKE C (NCT06853535)
- Testing
- The ticagrelor, The Clopidogrel
- Where
- China
- Volunteers
- 5,138 people
- Sponsor
- Sichuan Provincial People's Hospital
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Ischemic Stroke, TIA (Transient Ischemic Attack)
Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic Stroke
The goal of this observational study is to explore the potential efficacy of related biomakers in predicting clopidogrel resistance in patients with ischemic stroke. To be specific : 1.
- Conditions
- Ischemic Stroke, TIA (Transient Ischemic Attack), Clopidogrel Resistance
- Trial name
- NCT06753149
- Volunteers
- 800 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Metabolism of Clopidogrel
Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug.
- Trial name
- PGXB2B (NCT01341600)
- Testing
- Clopidogrel, Omeprazole/Clopidogrel
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Thromboembolic Stroke, Aspirin
The Prevention of Thromboembolic Complications Associated With Coil Embolization
Clopidogrel has been to be reported to be superior to aspirin for the prevention of thromboembolic complications associated with coil embolization in patients with ruptured aneurysms.
- Conditions
- Thromboembolic Stroke, Aspirin, Clopidogrel, Coil Embolization
- Trial name
- NCT05512546
- Testing
- Aspir-Low Pill
- Where
- Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Muhammad Hassan
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Acute Coronary Syndrome, Bleeding
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome
A retrospective real world analysis of bleeding events with ticagrelor compared to clopidogrel in ACS patients.
- Conditions
- Acute Coronary Syndrome, Bleeding, Novel Anti-platelets, Ticagrelor
- Trial name
- ROBOT-ACS (NCT02484924)
- Testing
- Ticagrelor
- Where
- United Kingdom
- Volunteers
- 5,225 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
PTRG-DES Consortium
The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea.
- Conditions
- Coronary Artery Disease, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Stent Thrombosis
- Trial name
- PTRG (NCT04734028)
- Testing
- Clopidogrel Tablets
- Where
- South Korea
- Volunteers
- 13,160 people
- Sponsor
- Gyeongsang National University Hospital
Hip Fractures, Clopidogrel, Poor Metabolism of
Aggregometry in Elderlies With Hip Fracture and Receiving Clopidogrel
In elderly patients, hip fracture should be surgically treated within 48 hours from admission, since its deferral worsens the mortality.
- Conditions
- Hip Fractures, Clopidogrel, Poor Metabolism of, Anesthesia
- Trial name
- NCT04642209
- Testing
- Aggregometry
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- University Magna Graecia
Blood Loss, Surgical, Ticagrelor
Comparison of CABG Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel
In patients with coronary artery disease, dual antiplatelet therapy (acetylsalicylic acid and a P2Y12-receptor antagonist) is a commonly used method because of its excellent antithrombotic effect.
- Conditions
- Blood Loss, Surgical, Ticagrelor, Clopidogrel
- Trial name
- CABG (NCT04431349)
- Testing
- Ticagrelor 180mg, Clopidogrel 75mg
- Where
- South Korea
- Volunteers
- 1,097 people
- Sponsor
- Ajou University School of Medicine
Smoking Status, Genetic Risk Factors
Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Restenosis occurs for many different reasons. Over the years, many predictive clinical, biological, genetic, epigenetic, lesion-related, and procedural risk factors for restenosis have been identified.
- Conditions
- Smoking Status, Genetic Risk Factors, Restenosis, Clopidogrel
- Trial name
- NCT03613337
- Testing
- clinical restenosis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cui Yimin
Transient Ischemic Attack, Stroke
Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack
Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.
- Conditions
- Transient Ischemic Attack, Stroke, Aspirin, Clopidogrel
- Trial name
- NCT00363753
- Testing
- aspirin versus clopidogrel
- Where
- 2 sites in United States
- Sponsor
- University of California, San Diego
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Clopidogrel, Poor Metabolism of, Ischemic Stroke
Clopidogrel Resistance in Stroke Patients From Different Ethnicities
Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events.
- Trial name
- NCT03806894
- Testing
- Quantification of platelet aggregation
- Volunteers
- 300 people
- Sponsor
- Ziv Hospital
Blood Platelets, Clopidogrel
PACT (Platelet Activity After Clopidogrel Termination)
Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots. The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after…
- Trial name
- PACT (NCT00619073)
- Testing
- clopidogrel + aspirin, Aspirin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester